What is Iktos?
Founded in October 2016, Iktos is at the forefront of applying artificial intelligence to medicinal chemistry and new drug design. The company has developed proprietary deep learning generative models that enable the in silico design of molecules optimized for drug discovery projects, offering substantial productivity gains in pharmaceutical R&D. Iktos provides its innovative technology through professional services and its SaaS platform, Makya, while also developing Spaya, an AI-powered synthesis planning software. The company has recently broadened its research to include AI technologies for peptide-based therapeutics, developing advanced generative and predictive models for novel peptide design.
How much funding has Iktos raised?
Iktos has raised a total of $19M across 2 funding rounds:
Series A
$16.4M
Grant
$2.6M
Series A (2023): $16.4M with participation from Merck Ventures and Omnes Capital
Grant (2025): $2.6M led by The European Innovation Council
Key Investors in Iktos
The European Innovation Council
The European Innovation Council is an entity focused on fostering innovation within the European landscape, likely supporting cutting-edge research and development initiatives.
Merck Ventures
Merck Ventures, the corporate venture capital arm of Merck, specializes in investing in innovative technologies and products that have the potential to significantly impact core business areas, with a strong focus on early-stage investing and company creation.
Omnes Capital
Omnes Capital is a European private equity firm with a focus on energy transition and deeptech innovation, supporting high-performing companies and entrepreneurs.
What's next for Iktos?
The substantial enterprise-level funding and recent strategic investment signal a pivotal growth phase for Iktos. This capital infusion is expected to accelerate the development and commercialization of its AI-driven drug discovery platforms, Makya and Spaya, and further its expansion into the burgeoning field of peptide therapeutics. The company's focus on generating significant productivity gains in pharmaceutical R&D positions it for strong market adoption and potential partnerships within the biotech and pharmaceutical industries.
See full Iktos company page
